REPLIMUNE GROUP, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.00M, a 12450.00% increase year-over-year.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $281.00K, a 325.76% increase year-over-year.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $8.00K, a 87.88% decline year-over-year.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $66.00K.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for fiscal 2026 was $380.00K, a 42.32% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $267.00K, a 84.82% decline from fiscal 2024.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.76M, a 48.93% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $3.44M, a 49.81% decline from fiscal 2022.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $380.00K 10-K · filed 2026-06-29 | |
| 2025-12-31 | $281.00K 10-Q · filed 2026-02-03 | |
| 2025-06-30 | $8.00K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $267.00K 10-K · filed 2026-06-29 | |
| 2024-12-31 | $66.00K 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $103.00K 10-Q · filed 2026-02-03 | |
| 2024-06-30 | $66.00K 10-Q · filed 2026-02-03 | |
| 2024-03-31 | $1.76M 10-K · filed 2025-05-22 | |
| 2023-09-30 | $550.00K 10-Q · filed 2025-02-12 | |
| 2023-06-30 | $1.21M 10-Q · filed 2025-02-12 | |
| 2023-03-31 | $3.44M 10-K · filed 2024-05-16 | |
| 2022-12-31 | $500.00K 10-Q · filed 2024-02-08 | |
| 2022-09-30 | $1.11M 10-Q · filed 2024-02-08 | |
| 2022-06-30 | $1.56M 10-Q · filed 2024-02-08 | |
| 2022-03-31 | $6.86M 10-K · filed 2023-05-18 | |
| 2021-12-31 | $4.04M 10-Q · filed 2023-02-09 | |
| 2021-09-30 | $1.21M 10-Q · filed 2023-02-09 | |
| 2021-06-30 | $1.17M 10-Q · filed 2023-02-09 | |
| 2021-03-31 | $5.75M 10-K · filed 2022-05-19 | |
| 2020-12-31 | $3.07M 10-Q · filed 2022-02-03 | |
| 2020-09-30 | $291.00K 10-Q · filed 2022-02-03 | |
| 2020-06-30 | $1.55M 10-Q · filed 2022-02-03 | |
| 2020-03-31 | $551.00K 10-K · filed 2021-05-20 | |
| 2019-12-31 | $357.00K 10-Q · filed 2021-02-04 | $521.00K derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $105.00K 10-Q · filed 2021-02-04 | $317.00K derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-06-30 | $18.00K 10-Q · filed 2021-02-04 | $224.00K derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-03-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $206.00K 10-K · filed 2020-06-03 |
| 2018-12-31 | $153.00K 10-Q · filed 2020-02-13 | |
| 2018-09-30 | $12.00K 10-Q · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |